News

21

Sep
CL ends Gilead's dangerous games with lives of HepC patients in Malaysia Result of hard fought efforts of community-based groups, NGOs and treatment providers 20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG) in welcoming the ...

03

Aug
Ever since generic DAA made available in early 2015 with Gilead's VL to several Indian generic manufacturers, there has been some progress as well as challenges in the context of access to Hepatitis C treatment. During Asia Pacific AIDS and Co-infection conference in Hong Kong June 2017, Giten Khwahirakpam from ...

15

Feb
A joint press release between I-MAK, DNP+ and MSF Access Campaign on challenges to patents (patent oppositions) was filed in India on key hep C drugs sofosbuvir, daclatasvir and velpatasvir. New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat ...

29

Mar
For pricing and availability of generic Indian daclatasvir as on 7 March 2016, Please click here.